Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours

European Journal of Cancer

Volumn 50, Issue 5, 2014, Pages 902-911

  Meyer, Tim ^a,b   Qian, Wendi ^c,d   Caplin, Martyn E ^a   Armstrong, Graham ^c   Lao Sirieix, Si Houy ^c   Hardy, Richard ^c   Valle, Juan W ^e   Talbot, Denis C ^f   Cunningham, David ^g   Reed, Nick ^h   Shaw, Ashley ^c   Navalkissoor, Shaunak ^a   Luong, Tu Vinh ^a   Corrie, Pippa G ^c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d MRC BIOSTATISTICS UNIT   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f CHURCHILL HOSPITAL   (United Kingdom)

^g Gastrointestinal Research Unit   (United Kingdom)

^h BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

Capecitabine; Chemotherapy; Cisplatin; Neuroendocrine tumour; Phase II; Randomised clinical trial; Streptozocin

Indexed keywords

CAPECITABINE; CISPLATIN; STREPTOZOCIN;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GLUCOSE BLOOD LEVEL; HAND FOOT SYNDROME; HEARING DISORDER; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

CAPECITABINE; CHEMOTHERAPY; CISPLATIN; NEUROENDOCRINE TUMOUR; PHASE II; RANDOMISED CLINICAL TRIAL; STREPTOZOCIN;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; STREPTOZOCIN; TREATMENT OUTCOME;

EID: 84896707141     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.12.011     Document Type: Article

References (26)

1. C.G. Moertel, J.A. Hanley, and L.A. Johnson Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma N Engl J Med 303 1980 1189 1194
2. P.F. Engstrom, P.T. Lavin, C.G. Moertel, E. Folsch, and H.O. Douglass Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor J Clin Oncol 2 1984 1255 1259
3. C.G. Moertel, M. Lefkopoulo, S. Lipsitz, R.G. Hahn, and D. Klaassen Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma N Engl J Med 326 1992 519 523
4. W. Sun, S. Lipsitz, P. Catalano, J.A. Mailliard, D.G. Haller, and Eastern Cooperative Oncology Group Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 J Clin Oncol 23 2005 4897 4904
5. E. Rivera, and J.A. Ajani Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma Am J Clin Oncol 21 1998 36 38
6. P.N. Cheng, and L.B. Saltz Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma Cancer 86 1999 944 948
7. M.A. Gonzalez, S. Biswas, L. Clifton, and P.G. Corrie Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin Br J Cancer 89 2003 455 456
8. M.A. Kouvaraki, J.A. Ajani, and P. Hoff et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas J Clin Oncol 22 2004 4762 4771
9. T. Delaunoit, M. Ducreux, and V. Boige et al. The doxorubicin- streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 40 2004 515 520
10. A.D. McCollum, M.H. Kulke, and D.P. Ryan et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors Am J Clin Oncol 27 2004 485 488
11. N.C. Turner, S.J. Strauss, and D. Sarker et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours Br J Cancer 102 2010 1106 1112
12. K. Weatherstone, and T. Meyer Streptozocin-based chemotherapy is not history in neuroendocrine tumours Target Oncol 7 2012 161 168
13. R. Porschen, H.T. Arkenau, and S. Kubicka et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group J Clin Oncol 25 2007 4217 4223
14. D. Cunningham, N. Starling, and S. Rao et al. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
15. P.M. Hoff, R. Ansari, and G. Batist et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 2001 2282 2292
16. L. Medley, A.N. Morel, and D. Farrugia et al. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours Br J Cancer 104 2011 1067 1070
17. E. Mitry, T. Walter, and E. Baudin et al. Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study) J Clin Oncol 30 May 20 Suppl. 2012 4071
18. J.R. Strosberg, R.L. Fine, and J. Choi et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas Cancer 117 2011 268 275 10.1002/cncr.25425
19. M.S. Khan, T.V. Luong, and J. Watkins et al. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms Br J Cancer 108 9 2013 1838 1845
20. G. Rindi, G. Klöppel, and H. Alhman European Neuroendocrine Tumor Society (ENETS) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system Virchows Arch 449 2006 395 401
21. M.H. Kulke, K. Stuart, and P.C. Enzinger et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors J Clin Oncol 24 2006 401 406
22. J.A. Chan, K. Stuart, and C.C. Earle et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors J Clin Oncol 30 2012 2963 2968
23. M. Ducreux, J.-F. Seitz, and D. Smith et al. Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of patients with metastatic well-differentiated duodeno-pancreatic endocrine tumors (BETTER study) J Clin Oncol 30 May 20 Suppl. 2012 4036
24. E. Raymond, L. Dahan, and J.L. Raoul et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 501 513
25. J.C. Yao, M.H. Shah, and T. Ito RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
26. S. Ekeblad, A. Sundin, and E.T. Janson et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors Clin Cancer Res 13 2007 2986 2991